Fotouhi, Nader
- Global Alliance for Tb Drug Development (no department on record)
From the FY2023 NIH awards this investigator leads as contact PI. The department is the award's.
FY2023 NIH rank #622
- Sustained Excellence
- Top 5% Funded
- Early Career
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID unavailableSearch this ID in NIH RePORTER
- ORCID iD
- No ORCID iD on recordA researcher can add one by claiming this profile.
- ScienceDex PI coverage
- FY2019 through FY2023Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2023
Linked Award Amount
$5.5M
Full award amounts, FY2023
Award Records
1
Records listing this PI
Award-Linked Rank
#622
By linked amount among FY2023 PIs
Earliest Year Loaded
2019
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2023 award records by amount
NIH award records listing Fotouhi, Nader as a PI. Multi-PI records show the full award amount for context.
- 5U19AI142735-05U19Contact PIModulation of Protein production and Degradation as an integrated approach to rapid sterilization of Drug sensitive and resistant Mtb.$5.5Maward amount
Award organization
Organizations that administered FY2023 awards listing Fotouhi, Nader as a PI.
FY2023 award administered by Global Alliance for Tb Drug Development (NY).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2019First NIH AwardGlobal Alliance for Tb Drug Development
- 2019$500K Cumulative Funding
- 2019$1M Cumulative Funding
- 2019$2M Cumulative Funding
- 2019$5M Cumulative Funding
- 2019Entered Top 50% NationallyRanked #554
- 2019Entered Top 25% NationallyRanked #554
- 2019Entered Top 10% NationallyRanked #554
- 2019Entered Top 5% NationallyRanked #554
- 2020$10M Cumulative Funding
- 2020Entered Top 1% NationallyRanked #155
- 2023$25M Cumulative Funding